Browsing by Author "Kozanoglu, I."
Now showing 1 - 20 of 29
- Results Per Page
- Sort Options
Item The Analysis of Patients with Poor Mobilization and Mobilization Failure: Can Rdw Be A Predictive Factor?(2016) Buyukkurt, N.; Aytan, P.; Kozanoglu, I.; Maytalman, E.; Yeral, M.; Gereklioglu, C.; Solmaz, S.; Korur, A.; Ozdogu, H.; Boga, C.; 0000-0002-0895-4787; 0000-0002-5268-1210; 0000-0001-5284-7439; 0000-0002-9580-628X; 0000-0002-8902-1283; 0000-0002-2553-7715; 0000-0002-9680-1958; AAE-1457-2021; AAE-1241-2021; F-6265-2019; ABC-4148-2020; AAD-5542-2021; AAD-6222-2021; AAE-3833-2019Item Association of Chronic Lymphocytic Leukemia and Acute Myelobastic Leukemia in Three Patients; Cases with the Concomitant Presence of Two Different Malignant Clones(2017) Yilmaz, M.; Kizikli, A.; Yeral, M.; Kozanoglu, I.; Durusoy, S.; Subari, S.; Cangi, S.; 0000-0002-5710-5263; 0000-0002-9580-628X; 0000-0002-5268-1210; HKM-4739-2023; ABC-4148-2020; AAE-1241-2021Item Autologous Hematopoietic Stem Cell Transplantation for Severe Refractory Crohn's Disease: A Case Report(2014) Ozdogu, H.; Serin, E.; Boga, C.; Kozanoglu, I.; Yeral, M.; Gereklioglu, C.; https://orcid.org/0000-0002-8902-1283; https://orcid.org/0000-0002-0138-6107; https://orcid.org/0000-0002-9680-1958; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0002-9580-628X; AAD-5542-2021; AAM-7281-2021; AAD-6222-2021; AAE-1241-2021; ABC-4148-2020Item Comparison of High and Intermediate Dose Etoposide with G-Csf Priming for Peripheral Blood Stem Cell Mobilization(2014) Buyukkurt, N.; Yeral, M.; Kozanoglu, I.; Kasar, M.; Unver, G.; Boga, C.; Ozdogu, H.; https://orcid.org/0000-0002-0895-4787; https://orcid.org/0000-0002-9580-628X; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0003-3856-7005; https://orcid.org/0000-0002-9680-1958; https://orcid.org/0000-0002-8902-1283; AAE-1457-2021; ABC-4148-2020; AAE-1241-2021; AAL-3906-2021; AAD-6222-2021; AAD-5542-2021Item Comparison of Ishage-Based Cd34 (+) Cell Enumeration Protocols on BD Facs Canto II and Attune Flow Cytometers(2014) Kozanoglu, I.; Unver, G.; Sariturk, C.; Baran, Y.; Yeral, M.; Boga, C.; Ozdogu, H.; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0002-4130-1059; https://orcid.org/0000-0002-9580-628X; https://orcid.org/0000-0002-9680-1958; https://orcid.org/0000-0002-8902-1283; AAE-1241-2021; AAS-7129-2021; ABC-4148-2020; AAD-6222-2021; AAD-5542-2021Item Comparison Of The Conditioning Regimens with or without TBI in Acute Lymphoblastic Leukemia Patients: Experience of A Single Center(2015) Yeral, M.; Boga, C.; Ozdogu, H.; Solmaz, S.; Korur, A. P.; Asma, S.; Kozanoglu, I.; 0000-0002-9580-628X; 0000-0002-5268-1210; 0000-0002-8902-1283; 0000-0002-9680-1958; ABC-4148-2020; AAE-1241-2021; AAD-5542-2021; AAD-6222-2021Item Cytogenetic Features of Acute Leukemia Patients Treated at a Single Center at East Mediterenian and South Region of Turkey(2019) Aktekin, E.; Yazici, N.; Erbay, A.; Celik, Z. Yilmaz; Kozanoglu, I.; Sarialioglu, F.Item Demodocidosis Accompanying Acute Cutaneous Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation(2017) Aytan, P.; Yeral, M.; Gereklioglu, C.; Kocer, N.; Buyukkurt, N.; Kozanoglu, I.; Ozdogu, H.; Boga, C.; 0000-0002-2553-7715; 0000-0002-9580-628X; 0000-0002-5943-9283; 0000-0002-0895-4787; 0000-0002-5268-1210; 0000-0002-8902-1283; AAE-3833-2019; ABC-4148-2020; AAM-5436-2021; AAE-1457-2021; AAE-1241-2021; AAD-5542-2021; AAD-6222-2021Item Discovering Alternative Targets in Chronic Myeloid Leukemia (Cml): Determination of Expression Levels of Bioactive Sphingolipid Genes in Newly Diagnosed and Drug-Resistant Cml Patients(2015) Yandim, M. Kartal; Kozanoglu, I.; Ozdogu, H.; Piskin, O.; Ozcan, M. A.; Saydam, G.; Sahin, F.; Avcu, F.; Ural, A. U.; Unal, A.; Baran, Y.; 0000-0002-5268-1210; AAE-1241-2021Item Effect of Levatirecetam Monotherapy on Complete Blood Count, Immunoglobulin Levels and Lymphocyte Subsets in Children and Adolescents with Epilepsy(2017) Misirlioglu, P. K.; Erol, I.; Savas, T.; Cagla, S.; Kozanoglu, I.; 0000-0002-3530-0463; 0000-0002-5268-1210; AAK-4825-2021; AAE-1241-2021Item Effectiveness of Fludarabine- and Busulfan-Based Conditioning Regimens in Patients With Acute Myeloblastic Leukemia: 8-Year Experience in a Single Center(2015) Kasar, M.; Asma, S.; Kozanoglu, I.; Maytalman, E.; Boga, C.; Ozdogu, H.; Yeral, M.; 0000-0001-5284-7439; 0000-0002-8902-1283; 0000-0001-5335-7976; 0000-0003-3856-7005; 0000-0002-9580-628X; 0000-0002-9680-1958; 0000-0002-5268-1210; 26036558; F-6265-2019; AAD-5542-2021; AAI-7831-2021; AAL-3906-2021; ABC-4148-2020; AAD-6222-2021; AAE-1241-2021Objective. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for acute myeloblastic leukemia (AML). Because the conditioning regimen of busulfan plus cyclophosphamide carries significant risks of toxicity, we evaluated the factors affecting survival after fludarabine replacement instead of cyclophosphamide. Methods. The study included 55 patients who underwent allo-HSCT for AML and received busulfan, fludarabine, and antithymocyte globulin (ATG). Results. Forty-eight patients received a myeloablative regimen; 7 patients received a reduced-intensity conditioning regimen. The neutrophil and platelet engraftment times were 12 days (range 9 to 20) and 12 days (range 7 to 19), respectively. Graft-vs-host disease (GvHD) developed in 10% and 50% of the patients, respectively. Seven patients received donor lymphocyte infusion. Of them, 5 patients developed grade I or II GvHD, one grade IV GvHD. The median follow-up period was 20.6 months. The predicted progression-free survival (PFS) at 1 and 3 years after transplantation was 78% and 74%, respectively. The overall survival (OS) at 1, 3, and 5 years was 76%, 74%, and 62%, respectively. Treatmen-trelated mortality (infection in 1 patient, GvI-ID in 2 patients) occurred in 3 patients (5.5%). Multivariate analysis revealed that OS and PFS were not influenced by age, dose of busulfan or ATG, or presence of cytomegalovirus antigenemia. Acute GvHD and pretransplantation minimal residual disease positivity negatively affected the transplant outcome. The presence of active disease at the time of transplantation was found as an independent risk factor for AML. Conclusions. Busulfan- and fiudarabine-based conditioning regimens are effective for AML, and have acceptable toxicity, morbidity, and mortality.Item Endothelial Progenitor Cells in Takayasu's Arteritis(2014) Bozkirli, E. D. Ersozlu; Keskek, S. O.; Kozanoglu, I.; Yucel, A. E.; https://orcid.org/0000-0002-5268-1210; AAE-1241-2021; I-6542-2012Item Expansion of Bone Marrow Derived Mesenchymal Stem Cells Using A Gmp Compliant Closed System Bioreactor and Quality Analysis of The Expanded Cells(2014) Kozanoglu, I.; Maytalman, E.; Bilir, P.; Unver, G.; Siber, C.; Boga, C.; Ozdogu, H.; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0001-5284-7439; https://orcid.org/0000-0002-9680-1958; https://orcid.org/0000-0002-8902-1283; AAE-1241-2021; F-6265-2019; AAD-6222-2021; AAD-5542-2021Item Expression Levels of Ceramide-Generating and Clearance Genes in Newly Diagnosed and Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Patients: an Attempt To Find Novel Targets(2014) Yandim, M. Kartal; Kozanoglu, I.; Ozdogu, H.; Piskin, O.; Ozcan, M. A.; Saydam, G.; Sahin, F.; Avcu, F.; Ural, A. U.; Baran, Y.; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0002-8902-1283; AAE-1241-2021; AAD-5542-2021Item Expression Levels of Ceramide-Metabolising Genes in Newly Diagnosed and Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia (CML) Patients: The Discovery of Novel Targets in CML(2014) Yandim, M. Kartal; Kozanoglu, I.; Ozdogu, H.; Piskin, O.; Ozcan, M.; Saydam, G.; Sahin, F.; Avcu, F.; Ural, A.; Unal, A.; Baran, Y.; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0002-8902-1283; AAE-1241-2021; AAD-5542-2021Item Expression Levels of Jak/Stat Signaling Genes in Newly Diagnosed, Drug Sensitive and Resistant Chronic Myeloid Leukemia Patients(2015) Kiraz, Y.; Saydam, G.; Sahin, F.; Kozanoglu, I.; Ozdogu, H.; Piskin, O.; Ozcan, M. A.; Avcu, F.; Ural, A. U.; Unal, A.; Baran, Y.; 0000-0002-5268-1210; AAE-1241-2021Item Guillain-Barre Syndrome Associated with Parvovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation(2014) Yeral, M.; Boga, C.; Buyukkurt, N.; Kozanoglu, I.; Ozdogu, H.; Gereklioglu, C.; Goksel, B. Karakurum; https://orcid.org/0000-0002-9580-628X; https://orcid.org/0000-0002-9680-1958; https://orcid.org/0000-0002-0895-4787; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0002-8902-1283; https://orcid.org/0000-0003-2766-2277; ABC-4148-2020; AAD-6222-2021; AAE-1457-2021; AAE-1241-2021; AAD-5542-2021; AAE-2609-2021Item High Levels of Endothelial Progenitor Cells Can Be Associated with Thrombosis in Patients with Behcet's Disease(2014) Bozkirli, E. D. E.; Keskek, S. O.; Kozanoglu, I.; Yucel, A. E.; https://orcid.org/0000-0002-5268-1210; https://orcid.org/0000-0002-4860-9072; 24774036; AAE-1241-2021Objective. Behcet's disease (BD) is a systemic disorder characterised by vasculitis. Endothelial progenitor cells are derived front the bone marrow and contribute to new vessel formation. The aim of this study was to investigate the level of endothelial progenitor cells in BD and BD-associated conditions. Methods. A total of 74 subjects were included in this study, of whom 44 and 30 subjects were patients with BD or healthy subjects, respectively. Endothelial progenitor cells were defined and measured by flow cytometry according to the expression of CD146, CD31 and CD34. We separated BD patients according to the active disease, pathergy test results, thrombosis and gender. MedCalc 12.5 software programme was used for statistical analyses. Results. The level of endothelial progenitor cells was comparable in patients with BD and healthy subjects (p=0.849). It was also comparable in patients with active or inactive BD (p=0.320). The level of endothelial progenitor cells was higher in patients with thrombosis (p=0.04). There was no statistical significant difference between pathergy positive and negative patients (p-=0.969). The level of endothelial progenitor cells was not correlated with age, C-reactive protein, erythrocyte sedimentation rate, white blood cells and disease duration (p>0.05). Conclusion. The level of endothelial progenitor cells was significantly higher in BD patients with thrombosis. On the other hand, they were not associated with disease activity, pathergy test and other conditions. EPCs may be a useful marker for thrombosis in patients with BD. In our opinion, this is the most expected result in this study.Item How hematopoietic stem cell transplantation activity was affected during the pandemic? JACIE accredited center reflex(2022) Kozanoglu, I.; Tepebasi, S.; Kursun, E.; Sen, N.; Unsal, Z. E.; Kis, C.; Boga, C.; Yesilagac, H.; Demiroglu, Y. Z.; Pocan, G.Item The Importance of External Quality Control for CD34 Positive Stem Cells(2015) Unver, G.; Kozanoglu, I.; Kaya, T.; Asar, E.; Maytalman, E.; Aydin, L.; Ozdogu, H.; Boga, C.; 0000-0001-5284-7439; 0000-0003-0483-2333; 0000-0002-5268-1210; 0000-0002-8902-1283; 0000-0002-9680-1958; F-6265-2019; AAC-5750-2022; L-6337-2019; AAE-1241-2021; AAD-5542-2021; AAD-6222-2021